(Q46143449)

19 December 2017

title

Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis (English)

1 reference

19 December 2017

0 references

1 reference

19 December 2017

Robert N Baldassano

object named as

Robert N Baldassano

1 reference

19 December 2017

author name string

Erasmo Miele

1 reference

19 December 2017

Filomena Pascarella

1 reference

19 December 2017

Eleonora Giannetti

1 reference

19 December 2017

Lucia Quaglietta

1 reference

19 December 2017

language of work or name

English

0 references

publication date

20 January 2009

1 reference

19 December 2017

The American Journal of Gastroenterology

published in

1 reference

19 December 2017

volume

104

1 reference

19 December 2017

issue

1 reference

19 December 2017

page(s)

437-443

1 reference

19 December 2017

Inflammatory bowel disease in pediatric and adolescent patients

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Probiotics in man and animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Microbial influences in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

VSL#3: an analysis of basic and clinical contributions in probiotic therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

A basic program for constructing a dispensing list for a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

A new look at Crohn's disease: breakdown of the mucosal antibacterial defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

A pilot trial of Saccharomyces boulardii in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Probiotic bacteria enhance murine and human intestinal epithelial barrier function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Variable response to probiotics in two models of experimental colitis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2008.118

21 January 2018

Identifiers

DOI

10.1038/AJG.2008.118

1 reference

19 December 2017

1 reference

19 December 2017